(USD) | Jun 2024 | Q/Q |
---|---|---|
Revenue | 800.7MM | +11% |
Gross Profit | 384.6MM | +9% |
Cost Of Revenue | 416.1MM | +13% |
Operating Income | 48.1MM | -26% |
Operating Expenses | 336.5MM | +17% |
Net Income | 7.6MM | -85% |
R&D | 92.2MM | +13% |
G&A | 221.3MM | +13% |
Professional Service | - | - |
Amortization | 25.1MM | +55% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.
Bruker Corporation's ( NASDAQ:BRKR ) robust recent earnings didn't do much to move the stock. We think this is due to...
SEOUL, South Korea, August 13, 2024--Bruker Corporation is pleased to announce the successful installation and acceptance of a 1.2 GHz Avance® Nuclear Magnetic Resonance (NMR) spectrometer at the Korea Basic Science Institute (KBSI), just in time before the start of the ICMRBS 2024 conference in Korea. As the first 1.2 GHz NMR system in the Asia-Pacific region, it sets a new benchmark for molecular, cell biology and disease research by ultra-high field NMR.
Bruker ( NASDAQ:BRKR ) Second Quarter 2024 Results Key Financial Results Revenue: US$800.7m (up 17% from 2Q 2023). Net...
Evaluate Bruker's (BRKR) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
The London Company, an investment management company, released “The London Company SMID Cap Strategy” second quarter 2024 investor letter. A copy of the same can be downloaded here. US markets posted mixed results in Q2. The portfolio fell 5.7% (5.9%, net) compared to a 4.3% decrease for the Russell 2500 Index. Both stock selection and sector […]
BILLERICA, Mass., August 12, 2024--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on September 16, 2024 to stockholders of record as of September 2, 2024.
As major U.S. indexes experience a volatile period, with the S&P 500 and Nasdaq poised for their fourth straight weekly loss, investors are increasingly looking for stable opportunities amidst the fluctuations. In such an environment, growth companies with high insider ownership can offer a compelling investment case due to the confidence insiders demonstrate in their own businesses.
Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.